Global Genome Editing Market Size To Worth USD 34.75 Billion By 2033 | CAGR Of 16.19%
The Global Genome Editing Market Size was Valued at USD 7.75 Billion in 2023 and the Worldwide Genome Editing Market…
16,595€
15,16%
Echtzeit-Aktienkurs Intellia Therapeutics Inc.
Bid:
Ask:
Nachrichten zur Intellia Therapeutics Inc. Aktie
Intellia Therapeutics Announces Positive Long-Term Data from Ongoing Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)
CAMBRIDGE, Mass., June 02, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company…
Intellia Therapeutics: 3 Near-Term Pivotal In Vivo Gene Therapies
…
Earnings call: Intellia Therapeutics reports robust Q1 progress By Investing.com
Earnings call: Intellia Therapeutics reports robust Q1 progress…
Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2024 Earnings and Company Updates
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company…
Is Intellia Therapeutics Stock a Buy Now?
The companys future will depend on its innovative qualities.…
Intellia Therapeutics Stock Has 119% Upside, According to 1 Wall Street Analyst
2024 could see the start of its first late-stage clinical trials.…